Geneva’s decision to explore medical cocaine prescriptions as a response to its escalating crack crisis has sent shockwaves through Switzerland’s famously pragmatic approach to drug policy. The city, a hub of international diplomacy and cautious modernity, is now at the center of a debate that blurs the line between public health and moral hazard. What began as a localized emergency—overdose rates climbing 22% in 2025, emergency rooms overwhelmed by chronic users—has evolved into a national reckoning with the limits of prohibition. This is not just a story about drugs. it’s a test of whether a society can confront its contradictions with both empathy and hard data.
A Controversial Prescription: Medical Cocaine in a City Known for Neutrality
Switzerland’s reputation as a neutral, orderly nation has long shielded it from the visceral extremes of the global drug war. Yet Geneva’s pilot program, which would allow licensed physicians to prescribe pharmaceutical-grade cocaine to long-term users, challenges that image. The initiative, backed by local health officials and supported by a coalition of harm reduction advocates, aims to replace the chaotic, often lethal supply chain of street crack with a controlled, medical alternative. “This isn’t about normalizing addiction,” says Dr. Léa Moreau, a Geneva-based addiction specialist. “It’s about saving lives when other interventions have failed.”
The proposal hinges on a simple but radical premise: that addiction is a chronic illness, not a moral failing. By providing a legal, purified dose, the program seeks to reduce the risks of overdose, theft, and violence associated with the black market. Yet the plan has drawn fierce criticism from conservative lawmakers and religious groups, who argue it sends the wrong message about drug use. “This is a slippery slope,” warns Christian Democrat MP François Dufresne. “If we start prescribing cocaine, where does it end? Heroin? Meth?”
The Science Behind the Policy Shift
Geneva’s approach is not entirely unprecedented. The city has long been a pioneer in harm reduction, operating one of Europe’s first supervised injection sites, Injekt, since 2001. These facilities have been shown to reduce overdose deaths by 30% and connect users with treatment services. But medical cocaine prescriptions represent a quantum leap in both scope and controversy. The program would require rigorous monitoring, including regular health assessments and mandatory participation in therapy sessions. Patients would receive the drug in a clinical setting, administered by trained professionals.
Supporters point to a 2023 study published in The Lancet Psychiatry, which found that supervised medical use of stimulants like cocaine significantly reduced relapse rates and improved quality of life for chronic users. “This isn’t about enabling addiction,” explains Dr. Marcus Lin, a neuroscientist at the University of Zurich. “It’s about addressing the biological and psychological drivers of dependency. When people have a stable, predictable dose, they’re more likely to engage with recovery programs.”
But the policy’s success depends on overcoming deep-seated stigma. In Switzerland, cocaine is classified as a Schedule I drug, alongside heroin and LSD. Legalizing even limited medical use would require a complex legislative overhaul, including exemptions under the country’s strict narcotics laws. The Swiss Federal Office of Public Health has yet to comment, but the proposal has already sparked a national conversation about the ethics of drug policy.
International Precedents and the Global Drug Debate
Geneva’s plan echoes similar experiments in other parts of the world, though none have gone as far. In 2022, Portugal—renowned for decriminalizing all drugs—began piloting a program offering pharmaceutical-grade heroin to opioid users. The results were promising: a 40% drop in overdose deaths and increased access to treatment. Yet Portugal’s approach remains a niche experiment, while Geneva’s proposal could set a new precedent for how Western nations address stimulant use.
The move also raises questions about the global war on drugs. For decades, governments have relied on punitive measures, often at the expense of public health. But as overdose deaths reach record highs—over 100,000 in the U.S. Alone in 2024—pressure is mounting to rethink these strategies. “This is part of a broader shift,” says Dr. Nadia Khan, a policy analyst at the Global Drug Policy Institute. “Countries are starting to recognize that prohibition doesn’t work. What’s needed is a public health framework that prioritizes dignity over punishment.”
However, the path forward is fraught with challenges. Critics warn that medical cocaine programs could inadvertently fuel demand, creating a new class of dependent users. There are also concerns about the long-term effects of chronic cocaine use, even in a clinical setting. “We don’t yet have enough data on how this will play out,” notes Dr. Sophie Bell, a psychiatrist at the University of Geneva. “This is a high-stakes gamble, and the consequences could be severe.”
The Human Cost of the Crisis
Beneath the policy debates and expert analyses lies a human story. For individuals like 34-year-old Marco Delgado, a former construction worker who has struggled with crack addiction for over a decade, the proposal offers a glimmer of hope. “I’ve tried everything—detox centers, rehab, even counseling,” he says. “But the only time I feel in control is when I’m using the drug in a safe environment. This could be the difference between surviving and actually living.”
Yet for others, the idea is deeply unsettling. “I don’t want to see my son in a clinic getting a prescription for cocaine,” says Martine Dubois, a mother of two. “This feels like a failure of our society. We should be helping people recover, not giving them a legal way to keep using.”
The divide reflects a broader tension in modern drug policy: the balance between compassion and caution. Geneva’s experiment will be watched closely
